Emerging role of microRNAs to tackle drug resistance in pancreatic cancer

Gut

Volumn 64, Issue 12, 2015, Pages 1842-1843

  Neesse, Albrecht ^a   Gress, Thomas M ^b  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 17 92; MOCETINOSTAT; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

CANCER CHEMOTHERAPY; CANCER RESISTANCE; CANCER STEM CELL; CELL REPROGRAMMING TECHNIQUE; CHEMOSENSITIVITY; EPIGENETICS; HUMAN; NONHUMAN; NOTE; PANCREAS CANCER; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; DRUG RESISTANCE; FEMALE; GENETICS; METABOLISM; PANCREAS CARCINOMA; PANCREAS TUMOR;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CARCINOMA, PANCREATIC DUCTAL; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICRORNAS; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS;

EID: 84954373531     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309503     Document Type: Note

References (10)

1. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med 2011;17:313-19.
2. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
3. Cioffi M, Trabulo SM, Sanchez-Ripoll Y, et al. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Gut 2015;64: 1936-48.
4. Sainz B Jr, Alcala S, Garcia E, et al. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut 2015;64:1921-35.
5. Ozdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 2014;25:719-34.
6. Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 2014;25:735-47.
7. Sherman MH, Yu RT, Engle DD, et al. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 2014;159:80-93.
8. Duluc C, Moatassim-Billah S, Chalabi-Dchar M, et al. Pharmacological targeting of the protein synthesis mTOR/4E-BP1 pathway in cancer-associated fibroblasts abrogates pancreatic tumour chemoresistance. EMBO Mol Med Published Online First: 1 Apr 2015.
9. Singh SK, Chen NM, Hessmann E, et al. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J 2015;34:517-30.
10. Meidhof S, Brabletz S, Lehmann W, et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol Med Published Online First: 14 Apr 2015.